Zolpidem

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Zolpidem

Examples of brand names: Stilnox [DE]

ATC code: N05CF02

Main use (for orientation): Sleep disorders

Documented research summary

A combination with synthetic nabilone is not THC or CBN evidence. Separate animal comparator arms are not presented as co-administration.

Uncertainties and limitations

Edluar label revised in 2022, currently accessed. Nabilone is synthetic and considered separately; no general statement of combination safety.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Zolpidem: hepatic breakdown and sedation; consider formulation.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Zolpidem tartrate (sublingual Edluar), active substance; do not equate with all prolonged-release formulations.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0079]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: EDLUAR (ZOLPIDEM TARTRATE) TABLET [VIATRIS SPECIALTY LLC] [CA_L_D0079]

Source role [CA_P_27085870]: Scope distinction / context

Statement supported: Combination with nabilone, not with a registered phytocannabinoid.

Source: Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. [CA_P_27085870]

Source role [CA_P_39528623]: Scope distinction / context

Statement supported: CBN and zolpidem as comparator treatments, no established combination of the pair.

Source: A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats. [CA_P_39528623]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0079] EDLUAR (ZOLPIDEM TARTRATE) TABLET [VIATRIS SPECIALTY LLC]

Original source / bibliographic reference

Authors: Viatris Specialty LLC

Year: 2022

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_27085870] Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Original source / bibliographic reference

Authors: Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Year: 2016

Source type: research-article; Randomized Controlled Trial; Journal Article

DOI: 10.1007/s00213-016-4298-6

PMID: 27085870

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_39528623] A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.

Original source / bibliographic reference

Authors: Arnold JC, Occelli Hanbury-Brown CV, Anderson LL, Bedoya-Pérez MA, Udoh M, Sharman LA, Raymond JS, Doohan PT, Ametovski A, McGregor IS.

Year: 2025

Source type: research-article; Journal Article

DOI: 10.1038/s41386-024-02018-7

PMID: 39528623

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility